What this chart shows
This is the market price over time — what investors have been willing to pay each day. It is NOT a "when to buy / when to sell" signal chart, and we are NOT telling you to trade based on where the lines are going next. When evidence supports a fair-value estimate, the report compares today’s price with that estimate. When it does not, the report shows what operating performance today’s price appears to require. The chart pattern is not the conclusion.
Price Chart
ZYDUSLIFE — BSE Daily Chart
Chart data from BSE via TradingView · For visual reference only
Investment Analysis
FY 2026 ANNUAL REVIEW · BASE THESIS
We publish one deep annual review per fiscal year. Quarterly check-ins appear in the ‘Quarterly Updates’ tab — like a diary. After FY 2027 results, we run a fresh thesis.
The verdict is fair value cannot yet be estimated reliably. Revenue, profit and returns show a healthy operating business, while falling receivable days support cash quality. Yet the valuation methods range from ₹127 to ₹1,024 per share, so there is no dependable fair value or margin-of-safety price today.
Analysis generated by AI for educational purposes. Not SEBI-registered investment advice. Verify every figure independently.
What you need to believe at this price
A reverse DCF starts with today's share price and asks what future owner cash earnings would have to occur to justify it; DCF means discounted cash flow, or translating future cash into today's money. No dependable reverse calculation is available here, so an exact required growth path would be invented. Qualitatively, paying ₹1,114.2 requires belief that specialty and regional growth will offset generic competition, current high margins will not collapse, acquisitions will convert into cash, and return on capital will stay healthy. Until those beliefs are converted into a reproducible cash path, the price implication remains unquantified.
Business Model
How this company makes money, and why customers keep paying.
Zydus Lifesciences develops, manufactures and sells medicines across India, North America, emerging markets and Europe, alongside consumer-wellness, medical-technology, active pharmaceutical ingredient and alliance businesses. Follow one medicine payment: a patient or care provider buys a prescribed product through the healthcare channel; the company earns revenue by supplying the finished formulation after research, regulatory approval, manufacturing, quality control and distribution. Exact customer credit terms are not disclosed here, so collection speed is best watched through receivable days. Important costs include ingredients, plants, compliance, research and development, or R&D, and selling support. Some cash must also return to equipment and working capital, the money tied up between making a product and collecting payment. What remains after those needs is owner cash earnings: cash the business could reinvest, repay as debt or return to shareholders. The practical takeaway is to follow product demand, approvals and launches, profit margins, collections, and the cash required to sustain production—not revenue alone.
Latest Developments
Recent developments and earnings that informed this analysis.
The completed year ended with broad operating momentum. India branded formulations outgrew the market, led by chronic therapies, while international formulations grew across emerging markets and Europe. In North America, base-business volumes, launches and rare-disease products supported progress. India launches included the Nivolumab biosimilar Tishtha, the Aflibercept biosimilar Anyra and semaglutide brands in a reusable pen; a biosimilar is a highly similar version of an existing biological medicine. The company also signed an agreement to acquire Assertio Holdings and the board approved a buy-back of up to Rs. 11,000 mn at Rs. 1,150 per share. These moves widen the product mix and return capital, but launches and acquisitions matter only if they earn good returns after research, integration and working-capital costs. Watch sales durability, regulatory execution, acquisition cash use and margins next.
Competitive Moat
What protects this business from competitors.
A moat means a durable advantage that makes it hard for rivals to take customers or profits. Zydus shows promising ingredients, not proof of an unbreakable moat: India formulations repeatedly outgrew the market; chronic products became a larger part of the portfolio; oncology retained leadership; consumer wellness held leading positions; and rare-disease, biosimilar and complex regulatory routes require specialised capability. Patient-support services can also deepen relationships beyond a prescription. These strengths matter because differentiated products may face less direct price competition than ordinary generics. The caution is decisive: pharmaceutical leadership can weaken when patents, approvals, quality, rival launches or pricing change. Treat the moat as moderate and execution-dependent; confirm it through sustained market outperformance, approvals, cash returns and stable margins.
Strategic Pivots
New bets management is making with your capital.
The strategy is moving the mix toward harder-to-copy and steadier healthcare demand: more chronic and super-specialty medicines in India, rare-disease and specialty products in North America, therapy-led portfolios in emerging markets, broader European coverage, and advanced biosimilars. The proposed Assertio purchase extends the specialty direction, while patient-support programs move engagement beyond simply supplying a prescription. This matters because a differentiated portfolio can reduce dependence on crowded generic products, though it also raises research, regulatory and integration demands. The investor test is whether this shift produces durable owner cash earnings and returns on capital rather than only more launches and revenue.
Market Opportunity
How large the opportunity is, and how much remains uncaptured.
Management & Governance
Who runs this company and how they treat shareholder money.
Management deserves measured credit for ending the year with healthy double-digit growth, exceeding profitability expectations, outperforming the India market, expanding internationally and moving into differentiated medicines. Receivable days fell across the measured period, supporting operational discipline. Management also says it is comfortable near one-times net debt to EBITDA; EBITDA means operating profit before interest, tax, depreciation and amortisation. Still, management quality is proved by outcomes over time, not confident commentary. The acquisition plan, higher working-capital needs and specialty spending create fresh tests. Watch integration, regulatory delivery, cash conversion, debt and returns on new investment before assigning exceptional marks.
🎯 Capital Allocation
Capital allocation means deciding whether cash should fund factories, research, acquisitions, debt reduction, dividends or buy-backs. Across FY22 to FY26, operating cash flow totalled ₹16,914.1 Cr and capital expenditure totalled ₹19,411.9 Cr, a capex-to-cash-flow ratio of 1.15x, showing an investment phase. The company also paid dividends and approved a buy-back, while gross debt ended at ₹12,496 Cr. This mix can build value if specialty products and added capacity earn more than their funding cost. Acquisition-related working capital has already weighed on operating cash flow, so the practical test is future owner cash earnings, debt control and return on capital—not the size of spending or payouts alone.
⚠️ AI-generated for informational purposes only. Not investment advice. Verify all figures independently. · Financial data sourced from Screener workbook.